Human Genome Sciences Shares Fall After FDA Documents Are Released


Published On: November 13th, 2010

Lupus has been a hard nut to crack for drug makers, with several trials failing in recent years.

Here is the original: 
Human Genome Sciences Shares Fall After FDA Documents Are Released

STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

Stop Panic Attacks
The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.

try-now

YouTube Video



Loading...


Did You Know Did you know:


Racial and ethnic minorities are more likely to live in heavily polluted neighborhoods and work in high-risk occupations with lower air quality. Disparities in living and working conditions play a critical role in the incidence and burden of asthma in these populations. The effects of these conditions are evident in the adverse health outcomes experienced by children and adults in minority communities

Related Posts

  • A.M. Vitals: FDA Approves Glaxo, Human Genome Sciences Lupus Drug
    New Lupus Option: The FDA approved a lupus treatment co-marketed by GlaxoSmithKline and Human Genome Sciences, the first lupus drug approved in more than 50 years, and one expected to eventually reach $1 billion in annual sales, the WSJ reports . The agency said studies suggest Benlysta, a bioengineered antibody that blocks a protein thought..
  • Human Genome Sciences Shows Public Offerings Work, Too
    With big pharma eager to throw hundreds of millions of dollars at companies with promising experimental drugs, it’s easy to forget that there’s another route for up-and-coming drug makers: Selling shares to the public. We were reminded of this fact by Human Genome Sciences, which said that a public offering expected to close next week..
  • SEC Alleges Insider Trading on Human Genome Sciences Drug Info
    The SEC alleges inside information about a Human Genome Sciences trial of an experimental hepatitis C drug made its way to hedge funds via a French doctor. ..
  • A.M. Vitals: Human Genome Sciences Rejects Glaxo’s $2.6 Billion Bid
    iStockphoto Here’s what’s making health news this morning: Glaxo Bids for Human Genome Sciences (WSJ): The U.K. company’s longtime research partner rejected the $2.6 billion offer, a wager by Glaxo on the prospects of drugs discovered using Human Genome Sciences technology. Veterans Department to Increase Mental Health Staffing (New York Times): In a move to..
  • Arena Shares Fall After FDA Document Raises Lorcaserin Safety Issues
    The FDA’s briefing document raised the issue of increased rates of malignant tumors in rodents taking high doses of the diet drug lorcaserin. ..
  • Teva Shares Fall After MS Drug Falls Short in Study
    Developing new drugs is a tricky business. Teva Pharmaceutical Industries and Active Biotech got a tough reminder of that today; shares in the companies fell after they said their experimental multiple-sclerosis drug, laquinimod, missed the main goal of a major study. ..
Leave a comment
Comments are closed.
« U.N. Asks for $164 Million in Aid As Haitian Cholera Outbreak Widens Pfizer Will Go Beyond 15% Job-Cut Target From Wyeth Deal »